BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fuu T, Iijima K, Kusama Y, Otsuki T, Kato H. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report. J Med Case Rep 2022;16:193. [PMID: 35581611 DOI: 10.1186/s13256-022-03426-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Guillaume Z, Allory Y, Auclin E, Gervais C, Auvray M, Rochand A, Mejean A, Audenet F, Vano YA, Oudard S, Thibault C. [Collecting duct carcinoma and renal medullary carcinoma in the age of new therapies]. Bull Cancer 2023:S0007-4551(23)00102-9. [PMID: 36906403 DOI: 10.1016/j.bulcan.2023.02.015] [Reference Citation Analysis]
2 Buti S, Trentini F, Sepe P, Claps M, Isella L, Verzoni E, Procopio G. BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients. Tumori 2022. [DOI: 10.1177/03008916221141483] [Reference Citation Analysis]
3 . Ipilimumab/nivolumab. Reactions Weekly 2022;1911:248-248. [DOI: 10.1007/s40278-022-17545-4] [Reference Citation Analysis]